Which has better earnings and valuation, GHRS or RLMD?

GH Research is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GH Research N/A N/A -$48.26M -$1.00 N/A Relmada Therapeutics N/A N/A -$57.38M -$0.90 N/A

Is GHRS or RLMD more profitable?

GH Research's return on equity of -20.07% beat Relmada Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets GH Research N/A -20.07% -19.41% Relmada Therapeutics N/A -47.52% -43.97%

Does the media prefer GHRS or RLMD?

In the previous week, GH Research and GH Research both had 1 articles in the media. Relmada Therapeutics' average media sentiment score of 0.51 beat GH Research's score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Relmada Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, CMPS or RLMD?

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Compass Pathways N/A N/A -$287.86M -$4.62 N/A Relmada Therapeutics N/A N/A -$57.38M -$0.90 N/A

Is CMPS or RLMD more profitable?

Relmada Therapeutics' return on equity of -47.52% beat Compass Pathways' return on equity. Company Net Margins Return on Equity Return on Assets Compass Pathways N/A -49.63% -13.08% Relmada Therapeutics N/A -47.52% -43.97%

Does the media refer more to CMPS or RLMD?

In the previous week, Compass Pathways had 1 more articles in the media than Relmada Therapeutics. MarketBeat recorded 2 mentions for Compass Pathways and 1 mentions for Relmada Therapeutics. Compass Pathways' average media sentiment score of 0.66 beat Relmada Therapeutics' score of 0.51 indicating that Compass Pathways is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Pathways 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relmada Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, TRLV or RLMD?

Trulieve Cannabis has higher revenue and earnings than Relmada Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trulieve Cannabis $1.14B 1.86 N/A N/A N/A Relmada Therapeutics N/A N/A -$57.38M -$0.90 N/A

Is TRLV or RLMD more profitable?

Trulieve Cannabis' return on equity of 0.00% beat Relmada Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Trulieve Cannabis N/A N/A N/A Relmada Therapeutics N/A -47.52% -43.97%

Does the media refer more to TRLV or RLMD?

In the previous week, Trulieve Cannabis and Trulieve Cannabis both had 1 articles in the media. Relmada Therapeutics' average media sentiment score of 0.51 beat Trulieve Cannabis' score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trulieve Cannabis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Relmada Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RLMD or PRGO?

In the previous week, Perrigo had 3 more articles in the media than Relmada Therapeutics. MarketBeat recorded 4 mentions for Perrigo and 1 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.51 beat Perrigo's score of 0.40 indicating that Relmada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Perrigo 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor RLMD or ANIP?

In the previous week, ANI Pharmaceuticals had 19 more articles in the media than Relmada Therapeutics. MarketBeat recorded 20 mentions for ANI Pharmaceuticals and 1 mentions for Relmada Therapeutics. ANI Pharmaceuticals' average media sentiment score of 0.74 beat Relmada Therapeutics' score of 0.51 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ANI Pharmaceuticals 12 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Relmada Therapeutics (RLMD) Competitors

$4.63 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Compare

RLMD vs. GHRS, CMPS, TRLV, PRGO, and ANIP

Should you buy Relmada Therapeutics stock or one of its competitors? Relmada Therapeutics's main competitors and comparable companies include GH Research (GHRS), Compass Pathways (CMPS), Trulieve Cannabis (TRLV), Perrigo (PRGO), and ANI Pharmaceuticals (ANIP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Relmada Therapeutics compare to GH Research?

GH Research (NASDAQ:GHRS) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

In the previous week, GH Research and GH Research both had 1 articles in the media. Relmada Therapeutics' average media sentiment score of 0.51 beat GH Research's score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Relmada Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GH Research is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$1.00	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A

GH Research has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market.

GH Research's return on equity of -20.07% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-20.07%	-19.41%
Relmada Therapeutics	N/A	-47.52%	-43.97%

GH Research currently has a consensus price target of $45.00, indicating a potential upside of 58.84%. Relmada Therapeutics has a consensus price target of $12.00, indicating a potential upside of 159.18%. Given Relmada Therapeutics' higher possible upside, analysts plainly believe Relmada Therapeutics is more favorable than GH Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

56.9% of GH Research shares are owned by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are owned by institutional investors. 14.5% of Relmada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

GH Research and Relmada Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Relmada Therapeutics compare to Compass Pathways?

Compass Pathways (NASDAQ:CMPS) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

Relmada Therapeutics' return on equity of -47.52% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-49.63%	-13.08%
Relmada Therapeutics	N/A	-47.52%	-43.97%

Compass Pathways currently has a consensus target price of $23.36, indicating a potential upside of 75.22%. Relmada Therapeutics has a consensus target price of $12.00, indicating a potential upside of 159.18%. Given Relmada Therapeutics' higher possible upside, analysts plainly believe Relmada Therapeutics is more favorable than Compass Pathways.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A

46.2% of Compass Pathways shares are held by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are held by institutional investors. 2.8% of Compass Pathways shares are held by insiders. Comparatively, 14.5% of Relmada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Compass Pathways has a beta of 2.5, meaning that its stock price is 150% more volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market.

In the previous week, Compass Pathways had 1 more articles in the media than Relmada Therapeutics. MarketBeat recorded 2 mentions for Compass Pathways and 1 mentions for Relmada Therapeutics. Compass Pathways' average media sentiment score of 0.66 beat Relmada Therapeutics' score of 0.51 indicating that Compass Pathways is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Pathways	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relmada Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Compass Pathways beats Relmada Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Relmada Therapeutics compare to Trulieve Cannabis?

Trulieve Cannabis (NYSE:TRLV) and Relmada Therapeutics (NASDAQ:RLMD) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

Trulieve Cannabis' return on equity of 0.00% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trulieve Cannabis	N/A	N/A	N/A
Relmada Therapeutics	N/A	-47.52%	-43.97%

45.2% of Relmada Therapeutics shares are owned by institutional investors. 3.8% of Trulieve Cannabis shares are owned by company insiders. Comparatively, 14.5% of Relmada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Trulieve Cannabis currently has a consensus price target of $15.00, suggesting a potential upside of 36.12%. Relmada Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 159.18%. Given Relmada Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Relmada Therapeutics is more favorable than Trulieve Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Trulieve Cannabis has higher revenue and earnings than Relmada Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trulieve Cannabis	$1.14B	1.86	N/A	N/A	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A

In the previous week, Trulieve Cannabis and Trulieve Cannabis both had 1 articles in the media. Relmada Therapeutics' average media sentiment score of 0.51 beat Trulieve Cannabis' score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trulieve Cannabis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Relmada Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Relmada Therapeutics beats Trulieve Cannabis on 7 of the 10 factors compared between the two stocks.

How does Relmada Therapeutics compare to Perrigo?

Relmada Therapeutics (NASDAQ:RLMD) and Perrigo (NYSE:PRGO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Relmada Therapeutics has a net margin of 0.00% compared to Perrigo's net margin of -41.85%. Perrigo's return on equity of 11.25% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-47.52%	-43.97%
Perrigo	-41.85%	11.25%	4.08%

Relmada Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 159.18%. Perrigo has a consensus price target of $19.33, indicating a potential upside of 35.96%. Given Relmada Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Relmada Therapeutics is more favorable than Perrigo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Perrigo had 3 more articles in the media than Relmada Therapeutics. MarketBeat recorded 4 mentions for Perrigo and 1 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.51 beat Perrigo's score of 0.40 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Perrigo	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Relmada Therapeutics has higher earnings, but lower revenue than Perrigo. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A
Perrigo	$4.14B	0.48	-$1.43B	-$12.51	N/A

45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 95.9% of Perrigo shares are owned by institutional investors. 14.5% of Relmada Therapeutics shares are owned by insiders. Comparatively, 0.4% of Perrigo shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Relmada Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market. Comparatively, Perrigo has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

Summary

Relmada Therapeutics beats Perrigo on 9 of the 16 factors compared between the two stocks.

How does Relmada Therapeutics compare to ANI Pharmaceuticals?

Relmada Therapeutics (NASDAQ:RLMD) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

ANI Pharmaceuticals has a net margin of 11.07% compared to Relmada Therapeutics' net margin of 0.00%. ANI Pharmaceuticals' return on equity of 27.37% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-47.52%	-43.97%
ANI Pharmaceuticals	11.07%	27.37%	10.47%

Relmada Therapeutics currently has a consensus target price of $12.00, indicating a potential upside of 159.18%. ANI Pharmaceuticals has a consensus target price of $105.83, indicating a potential upside of 40.46%. Given Relmada Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Relmada Therapeutics is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
ANI Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, ANI Pharmaceuticals had 19 more articles in the media than Relmada Therapeutics. MarketBeat recorded 20 mentions for ANI Pharmaceuticals and 1 mentions for Relmada Therapeutics. ANI Pharmaceuticals' average media sentiment score of 0.74 beat Relmada Therapeutics' score of 0.51 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ANI Pharmaceuticals	12 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 14.5% of Relmada Therapeutics shares are owned by company insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Relmada Therapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market.

ANI Pharmaceuticals has higher revenue and earnings than Relmada Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A
ANI Pharmaceuticals	$883.37M	1.96	$78.34M	$4.64	16.24

Summary

ANI Pharmaceuticals beats Relmada Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Relmada Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RLMD vs. The Competition

Export

Metric	Relmada Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$493.88M	$12.49B	$7.32B	$12.82B
Dividend Yield	N/A	2.62%	2.54%	10.78%
P/E Ratio	-5.14	789.79	272.91	24.33
Price / Sales	N/A	795.68	639.67	97.25
Price / Cash	N/A	15.47	29.03	36.90
Price / Book	3.92	10.52	11.33	6.42
Net Income	-$57.38M	$2.81B	$3.47B	$348.89M
7 Day Performance	-2.94%	2.51%	2.18%	0.51%
1 Month Performance	-10.62%	5.08%	7.61%	4.84%
1 Year Performance	638.44%	7.28%	25.16%	17.04%

Relmada Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RLMD Relmada Therapeutics	1.754 of 5 stars	$4.63 flat	$12.00 +159.2%	+638.4%	$493.88M	N/A	N/A	10
GHRS GH Research	1.9587 of 5 stars	$29.49 -1.6%	$45.00 +52.6%	+116.6%	$2.03B	N/A	N/A	10
CMPS Compass Pathways	2.457 of 5 stars	$13.75 +0.2%	$23.36 +69.8%	+189.2%	$1.91B	N/A	N/A	120	Analyst Downgrade Gap Up
TRLV Trulieve Cannabis	3.6407 of 5 stars	$9.65 +1.9%	$15.00 +55.4%	N/A	$1.85B	$1.14B	N/A	5,000	Gap Down
PRGO Perrigo	3.7365 of 5 stars	$13.06 +1.8%	$19.33 +48.1%	-41.9%	$1.81B	$4.14B	N/A	8,100	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RLMD) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Relmada Therapeutics (RLMD) Competitors

RLMD vs. GHRS, CMPS, TRLV, PRGO, and ANIP

How does Relmada Therapeutics compare to GH Research?

Summary

How does Relmada Therapeutics compare to Compass Pathways?

Summary

How does Relmada Therapeutics compare to Trulieve Cannabis?

Summary

How does Relmada Therapeutics compare to Perrigo?

Summary

How does Relmada Therapeutics compare to ANI Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLMD vs. The Competition

Relmada Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Relmada Therapeutics (RLMD) Competitors

RLMD vs. GHRS, CMPS, TRLV, PRGO, and ANIP

How does Relmada Therapeutics compare to GH Research?

Does the media prefer GHRS or RLMD?

Which has better earnings and valuation, GHRS or RLMD?

Which has more volatility & risk, GHRS or RLMD?

Is GHRS or RLMD more profitable?

Do analysts rate GHRS or RLMD?

Do institutionals & insiders hold more shares of GHRS or RLMD?

Summary

How does Relmada Therapeutics compare to Compass Pathways?

Is CMPS or RLMD more profitable?

Do analysts recommend CMPS or RLMD?

Which has better valuation & earnings, CMPS or RLMD?

Do insiders & institutionals hold more shares of CMPS or RLMD?

Which has more risk & volatility, CMPS or RLMD?

Does the media refer more to CMPS or RLMD?

Summary

How does Relmada Therapeutics compare to Trulieve Cannabis?

Is TRLV or RLMD more profitable?

Do insiders & institutionals have more ownership in TRLV or RLMD?

Do analysts prefer TRLV or RLMD?

Which has stronger earnings and valuation, TRLV or RLMD?

Does the media refer more to TRLV or RLMD?

Summary

How does Relmada Therapeutics compare to Perrigo?

Is RLMD or PRGO more profitable?

Do analysts recommend RLMD or PRGO?

Does the media favor RLMD or PRGO?

Which has preferable earnings & valuation, RLMD or PRGO?

Do insiders and institutionals believe in RLMD or PRGO?

Which has more volatility and risk, RLMD or PRGO?

Summary

How does Relmada Therapeutics compare to ANI Pharmaceuticals?

Is RLMD or ANIP more profitable?

Do analysts rate RLMD or ANIP?

Does the media favor RLMD or ANIP?

Do insiders and institutionals believe in RLMD or ANIP?

Which has more risk & volatility, RLMD or ANIP?

Which has preferable valuation and earnings, RLMD or ANIP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLMD vs. The Competition

Relmada Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools